Anavex Life Sciences Corp (AVXL)

[falconer66a]

When, Then? Now or Next Year?

I’ve previously posted that imo Anavex is not dependent on new FDA rules in order to initiate the next adaptive trial designs.

Ok, perhaps matters are so arranged that Anavex could begin any of their three new clinical trials under existing FDA trial conduct rules.

Should they do that; or, with a bit of patience (lacking for a number of posters here) wait and conduct the trails starting in third quarter 2018, but with far greater chances of success, with far more favorable new rules under the new protocols from the March 2018 hearings?

Do 'em now, with reduced, even questionable chances of outcomes (as a number of posters anticipate)? Or, wait until final, more favorable regs apply next year, thereby greatly increasing chances for results prompting FDA approval?

Which should our CEO elect to go with --- in the best interest of shareholders? Bet big now, or later, when the game is more favorable to Anavex?